Concord Drugs Limited has submitted its Independent Auditor's Review Report on both consolidated and standalone unaudited quarterly and year-to-date financial results for the quarter ended December 31, 2025. The review was conducted by Pundarikashyam and Associates, Chartered Accountants, in compliance with SEBI Regulation 33.

Corrigendum to Financial Results

The company issued a corrigendum on February 16, 2026, addressing an inadvertent omission in its original Q3FY26 financial results disclosure submitted on February 14, 2026. The update specifically relates to the complete implementation details of Labour Codes that were not fully reflected in the initial disclosure.

Labour Codes Implementation Update

The corrected disclosure provides comprehensive details about the Government of India's consolidation of 29 existing labour legislations into four unified Labour Codes. These codes became effective from November 21, 2025, though supporting rules are yet to be notified.

Auditor Review Details

The independent auditor's review was conducted for both consolidated and standalone financial results covering the quarter ended December 31, 2025, and year-to-date results from April 1, 2025, to December 31, 2025.

Subsidiary Performance

The consolidated results include performance from subsidiary Proton Remedies Private Limited. The subsidiary's financial contribution for the nine-month period shows steady operational performance.

Fund Raising and Utilization

The company disclosed details of its recent preferential issue and confirmed no deviation in fund utilization. The fundraising was completed in November 2025 with proper regulatory compliance.

Regulatory Compliance

The auditor confirmed that the financial statements comply with Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting and SEBI regulations. The company reported no outstanding defaults on loans and debt securities for the quarter ended December 31, 2025. The company continues to monitor the finalisation of Central and State Rules and clarifications from the Government regarding other aspects of the New Labour Code, having estimated and accounted for incremental liability for employees which is not material to the financial results.

Concord Drugs Limited has announced the receipt of significant purchase orders totaling approximately ₹14.71 crores from various government entities during December 2025. The pharmaceutical company disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as the order value exceeds the materiality threshold prescribed under the company's policy.

Order Details and Awarding Entities

The purchase orders have been secured from multiple government healthcare organizations across different states. The key awarding entities include Tamil Nadu Medical Services Corporation Ltd. (TNMSC), which has placed orders under two categories - 6 purchase orders under regular procurement and 32 purchase orders under the Mudhalvar Marundhagam Scheme.

Contract Specifications and Timeline

The orders are exclusively for domestic supply of various pharmaceutical products to government healthcare institutions. All contracts are with domestic entities, reinforcing the company's strong position in the Indian pharmaceutical market.

Regulatory Compliance and Impact

Concord Drugs Limited has confirmed that the promoter, promoter group, or group companies have no interest in the entities that awarded these orders. The transactions do not fall within related party transactions, ensuring arm's length dealings. The company expects these orders to have a positive impact on its business and operations, given the substantial value and involvement of major government healthcare procurement agencies.

The disclosure was made in accordance with SEBI regulations and the Master Circular dated November 11, 2024, demonstrating the company's commitment to transparency and regulatory compliance in its business operations.